OPTN (Option Therapeutics) Stock Based Compensation: $0.05 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Option Therapeutics Stock Based Compensation?

Option Therapeutics OPTN Stock Based Compensation is $0.05 Mil as of Dec. 2025.

Option Therapeutics's Stock Based Compensation for the three months ended in Dec. 2025 was $0.02 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was $0.05 Mil.

Option Therapeutics Stock Based Compensation Related Terms

Option Therapeutics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Option Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Option Therapeutics Stock Based Compensation Chart

Option Therapeutics Annual Data
Trend Jun24 Jun25
Stock Based Compensation
0.30 0.15

Option Therapeutics Quarterly Data
Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
Stock Based Compensation Get a 7-Day Free Trial 0.02 0.04 0.00 0.03 0.02

Option Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.05 Mil.

What does a Stock Based Compensation of $0.05 Mil mean?
Option Therapeutics (OPTN) has a Stock Based Compensation of $0.05 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Option Therapeutics and its competitors.
Is Option Therapeutics' Stock Based Compensation too high?
Option Therapeutics' current Stock Based Compensation is $0.05 Mil.
How does Option Therapeutics' Stock Based Compensation compare to ?
Option Therapeutics' Stock Based Compensation of $0.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Option Therapeutics and its competitors. Option Therapeutics's current Stock Based Compensation is $0.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Option Therapeutics stock overvalued right now?
Option Therapeutics (OPTN) has a current Stock Based Compensation of $0.05 Mil. The current Stock Based Compensation is $0.05 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Option Therapeutics (OPTN), the current Stock Based Compensation is $0.05 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Option Therapeutics Business Description

Comparable Companies
Address 680 West Nye Lane, Suite 201, Carson, NV, USA, 89703
Option Therapeutics Inc is a clinical-stage company developing inventive drug therapies to treat debilitating and life-threatening liver disease through its investigational drug candidate BIV201 (continuous infusion terlipressin). BIV201 is administered as a patent-pending liquid formulation of terlipressin with patents issued, to date, in the U.S., China, Japan, Chile, and India.